RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Clinical trial experience with Functional Assessment of Cancer Therapy—Lung in conventional and targeted non—small cell lung cancer therapy
Heyes, A. (2004). Clinical trial experience with Functional Assessment of Cancer Therapy—Lung in conventional and targeted non—small cell lung cancer therapy. Seminars in Oncology, 31(Suppl. 9), 16-22. https://doi.org/10.1053/j.seminoncol.2004.04.009
Advanced non—small cell lung cancer is associated with a low rate of long-term survival and a range of painful and debilitating symptoms. Various self-report questionnaires have been developed to monitor non—small cell lung cancer-related symptoms and quality of life over the course of treatment. The Functional Assessment of Cancer Therapy—Lung questionnaire is a widely used and well-validated lung cancer-specific instrument. It has been used to assess quality of life in numerous lung cancer clinical trials investigating a variety of therapeutic agents, including chemotherapy, radiation therapy, and targeted therapy. The Functional Assessment of Cancer Therapy—Lung is predictive of both tumor response and patient survival, and has been found to be highly sensitive to changes in clinical indicators.